The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial.

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

The FDA has approved Dupixent as an add-on maintenance therapy for adults with inadequately controlled COPD and an eosinophilic phenotype.

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...